Browse the evidence

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, constipation, dyspepsia) compared to placebo, which increases with dose and leads to higher discontinuation rates, but does not increase the risk of serious adverse events.

Tirzepatide is more likely to cause stomach issues like nausea and vomiting than a placebo, and these side effects are more common at higher doses. This can lead to some people stopping the medication, but it does not increase the risk of serious health problems. Managing these side effects is key to staying on the treatment.

Tirzepatide use is associated with a significantly higher incidence of adverse reactions, particularly nausea and diarrhea, which are dose-dependent and increase with higher doses (15mg).

Be prepared for potential side effects like nausea and diarrhea when starting Tirzepatide. These side effects are more likely at higher doses (15mg) and may decrease over time as your body adjusts. Most people tolerate the medication well, but it's important to discuss these potential side effects with your doctor.

Tirzepatide use is associated with a significantly increased incidence of adverse reactions, particularly gastrointestinal issues like nausea and diarrhea, which are dose-dependent.

Be prepared for potential side effects when starting Tirzepatide. Nausea and diarrhea are common, especially when you first start or increase the dose. These symptoms often improve over time. Starting at a lower dose (2.5mg) and gradually increasing can help your body adjust. Most people find the side effects manageable.

Obesity is a causal factor for many types of cancer, including colorectal, endometrial, kidney, and postmenopausal breast cancer.

Maintaining a healthy weight reduces your risk of developing several common cancers, including colorectal, kidney, and postmenopausal breast cancer.

Obesity increases the risk of estrogen-receptor-positive (ER+) breast cancer in postmenopausal women through the 'obesity-inflammation-aromatase axis,' where visceral fat produces estrogen via the enzyme aromatase.

For postmenopausal women, carrying extra weight around the middle is dangerous because fat cells act like small hormone factories. They convert other hormones into estrogen, which fuels the growth of many breast cancers. Losing weight reduces this local estrogen production and the inflammation that drives it, directly lowering your risk of developing estrogen-positive breast cancer.

GLP-1 receptor agonists reduce body weight primarily through central actions that induce satiety, rather than by increasing energy expenditure.

GLP-1 medications help you lose weight by making you feel full, not by boosting your metabolism. New oral versions exist, so you don't necessarily need injections.

Obesity is an independent, chronic non-communicable disease that directly causes cardiovascular disease through pathophysiological mechanisms including insulin resistance, endothelial dysfunction, and inflammation, rather than merely amplifying other risk factors.

Stop viewing obesity as just a lifestyle choice or a minor risk factor. It is a chronic disease with specific biological mechanisms (like inflammation and hormonal imbalance) that directly damage your heart and blood vessels. This means you deserve and need medical treatment, not just willpower-based advice, to manage it effectively and prevent heart disease.

GIP is the predominant incretin hormone in humans responsible for the majority of the incretin effect on postprandial insulin secretion, although its insulinotropic action is impaired in type 2 diabetes due to receptor downregulation.

Your body naturally produces GIP, which is the main hormone helping your pancreas release insulin after eating. In type 2 diabetes, this GIP signal gets weaker because the receptors on your insulin-producing cells become less sensitive. This is why treatments that target both GIP and GLP-1 receptors are often more effective than targeting GLP-1 alone.

In type 2 diabetes, the insulinotropic effect of GIP is significantly reduced or absent, primarily due to hyperglycemia-induced downregulation and degradation of the GIP receptor (GIPR) on beta cells.

In type 2 diabetes, your body still makes GIP, but your insulin cells stop listening to it because high blood sugar damages the receptors. This is reversible: lowering your blood sugar with medication or lifestyle changes can restore your body's natural ability to respond to GIP.

GLP1R agonists (like liraglutide) suppress food intake by acting on LepRbGlp1r neurons, but this pathway alone is insufficient for significant body weight loss.

GLP-1 drugs like liraglutide work partly by activating a specific brain pathway (LepRbGlp1r) that tells you to eat less. However, this pathway alone doesn't account for all the weight loss, meaning other brain areas are also involved. This suggests these drugs are complex and work on multiple levels.

SGLT2 inhibitors reduce cardiovascular risk (specifically heart failure) independently of, or partially mediated by, the modest weight loss achieved.

SGLT2 inhibitors are prescribed for diabetes, but they also significantly lower the risk of heart failure. This benefit is linked to the modest weight loss and metabolic changes the drug causes. Even if your blood sugar control doesn't change drastically, your heart health may improve.

Using assumed or estimated menstrual cycle phases (e.g., calendar-based counting) instead of direct biochemical verification (e.g., LH surge, progesterone levels) produces invalid and unreliable data in sport-related research.

Do not use calendar-based methods or apps to assign menstrual cycle phases in research or applied practice without biochemical verification. To accurately determine phases (e.g., follicular vs. luteal), you must measure biological markers such as urinary luteinizing hormone (LH) surges and serum/saliva progesterone levels. Relying on calendar counting alone is scientifically invalid due to high inter- and intra-individual variability in ovulation timing and the prevalence of subtle menstrual disturbances.

GLP-1 receptor agonists do not significantly increase the overall risk of cardiac arrhythmias (atrial fibrillation, atrial flutter, ventricular arrhythmias, or sudden cardiac death) in patients with type 2 diabetes or obesity compared to controls.

For patients with Type 2 Diabetes or Obesity, GLP-1 medications (like Ozempic, Trulicity, or Wegovy) are generally safe regarding heart rhythm. While they may slightly increase your resting heart rate, large studies show they do not increase the risk of serious heart rhythm problems like atrial fibrillation or ventricular arrhythmias compared to other treatments. However, those with very high BMI or on high doses should be monitored for ventricular arrhythmias.

Ketogenic diets are not recommended for Type 1 Diabetes or Gestational Diabetes due to safety concerns, lack of long-term data, and potential risks of DKA and fetal harm.

Do not use a ketogenic diet for Type 1 Diabetes or Gestational Diabetes. The risks of Diabetic Ketoacidosis (DKA) and potential harm to fetal development outweigh any potential glycemic benefits. Follow standard medical advice for these conditions.

Elevated plasma levels of endotrophin, the C-terminal cleavage product of collagen type VI alpha 3 (COL6A3), causally increase the risk of coronary artery disease, acting as a primary mediator linking obesity to cardiometabolic disease.

Obesity increases the risk of heart disease partly by raising levels of a specific protein fragment called endotrophin. This fragment is created when body fat increases, specifically from abdominal subcutaneous fat. The good news is that losing body fat reduces these levels. Therefore, weight loss interventions that reduce abdominal adiposity are likely to lower this specific biological risk factor for coronary artery disease.

Dapagliflozin (10 mg daily) improves cardiometabolic outcomes in patients hospitalized for myocardial infarction, regardless of diabetes status, by reducing the risk of heart failure hospitalization and death.

If you have had a heart attack, even if you don't have diabetes, taking dapagliflozin (10 mg daily) alongside your standard heart medications can significantly improve your recovery outcomes. It reduces the risk of future heart failure hospitalizations and death. The benefit is seen regardless of your diabetes status.

Bempedoic acid (180 mg daily) reduces major adverse cardiovascular events (MACE) in high-risk patients who are unable or unwilling to take statins, primarily by lowering LDL cholesterol and reducing coronary revascularization needs.

If you have high cholesterol and a history of heart disease but cannot take statins due to side effects, bempedoic acid (180 mg daily) is an effective alternative. It lowers LDL cholesterol and significantly reduces your risk of heart attack, stroke, and the need for coronary procedures. It is taken once daily.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of Heart Failure (HF) in a bodyweight-dependent manner, but also confer class-specific benefits beyond what is explained by weight or HbA1c changes alone.

If you have type 2 diabetes and are at risk for heart failure, SGLT2 inhibitors are the preferred class of medication. They reduce heart failure risk by 32% overall. This benefit comes from both weight loss (7% risk reduction per kg lost) and unique heart-protective effects that work even without significant weight change.

Obesity-related hypertension is mechanistically driven by visceral fat accumulation, leading to SNS and RAAS activation, sodium retention, and inflammation, which directly causes CKD progression.

Visceral fat is not just storage; it actively drives high blood pressure and kidney damage through hormones and inflammation. Managing visceral fat is key to preventing kidney disease.

Modifying the glycemic index of a high-quality dietary pattern (like DASH) does not improve cardiovascular risk factors or insulin sensitivity compared to a high-GI version of the same pattern.

Do not assume that choosing 'low GI' versions of healthy foods (like low-GI pasta or bread) offers extra cardiovascular benefits over standard versions if the overall diet is already healthy. Focus on the quality of the entire diet (e.g., DASH or Mediterranean patterns) rather than optimizing for glycemic index.

Metabolic bariatric surgery (MBS) is the most effective intervention for achieving long-term and sustained weight loss and can reverse certain metabolic defects like insulin resistance by altering gut hormone secretion.

For severe obesity, lifestyle changes alone are often insufficient. Metabolic bariatric surgery (like gastric bypass) is currently the most effective treatment for long-term weight loss and can reverse metabolic issues like diabetes by changing gut hormones.

Obesity is a chronic, progressive, relapsing, multifactorial neurobehavioral disease driven by complex brain-gut-adipose interactions, not merely a lack of willpower.

Stop blaming yourself for your weight. Obesity is a biological disease involving hormones and brain signaling, not a character flaw. Seek medical care that treats the underlying biology, not just willpower.

Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.

Maintaining a healthy weight reduces your risk of several cancers. Focus on sustainable lifestyle changes to lower your risk.

GLP-1 receptor agonists significantly increase the volume of retained gastric contents in fasting patients, but this does not translate to a statistically significant increase in actual pulmonary aspiration rates.

If you take a GLP-1 drug (like Ozempic or Wegovy) and have surgery, your stomach might stay fuller longer, but you are not significantly more likely to vomit into your lungs than someone who doesn't take it. Do not stop your medication without asking your surgeon or anesthesiologist, as modern guidelines suggest continuing it for most people while using other safety checks like ultrasound.